MedTrace Logo

Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH

NCT04347460 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-04-15

No results posted yet for this study

Summary

SARS-CoV2 has become a pandemic disease putting an enormous burden on health care systems around the world. A considerable amount of patients require intensive care treatment for Covid-19 associated pneumonia. At this point there is no specific treatment, apart from supportive intensive care treatment protocols for severe COVID-19 disease.The latest reports describe massive hyperinflammation in some of the severe COVID-19 patients, which is not a typical finding in virus associated pneumonia. The H-score and the modified HLH 2004 score offer diagnostic tools, that help establishing the diagnosis of HLH. Even more important is the expert clinical judgment to establish the diagnosis of sHLH.

Conditions

Sponsors & Collaborators

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Christoph Schmaderer, M.D. · Department of Nephrology, TUM Medical School, Klinikum rechts der Isar

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-27
Primary Completion
2020-07-01
Completion
2020-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04347460 on ClinicalTrials.gov